Market Closed -
Nyse
01:40:00 11/05/2024 am IST
|
5-day change
|
1st Jan Change
|
1.17
USD
|
-0.85%
|
|
+10.38%
|
+7.34%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
133.3
|
264
|
413
|
198.9
|
190.7
|
222.8
|
-
|
-
|
Enterprise Value (EV)
1 |
133.3
|
264
|
413
|
198.9
|
190.7
|
222.8
|
222.8
|
222.8
|
P/E ratio
|
-11.1
x
|
-12.6
x
|
-9.42
x
|
-7.8
x
|
-9.08
x
|
-10.4
x
|
-9.37
x
|
-10
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
37.9
x
|
145
x
|
95.1
x
|
13.5
x
|
21.3
x
|
12.7
x
|
15.2
x
|
6.64
x
|
EV / Revenue
|
37.9
x
|
145
x
|
95.1
x
|
13.5
x
|
21.3
x
|
12.7
x
|
15.2
x
|
6.64
x
|
EV / EBITDA
|
-3.73
x
|
-10.8
x
|
-8.54
x
|
-9.13
x
|
-7.93
x
|
-8.74
x
|
-9.61
x
|
-22.2
x
|
EV / FCF
|
-
|
-
|
-
|
308
x
|
-6.52
x
|
-42.8
x
|
-8.93
x
|
-9.4
x
|
FCF Yield
|
-
|
-
|
-
|
0.32%
|
-15.3%
|
-2.33%
|
-11.2%
|
-10.6%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,49,794
|
1,49,991
|
1,68,558
|
1,69,976
|
1,74,987
|
1,88,798
|
-
|
-
|
Reference price
2 |
0.8900
|
1.760
|
2.450
|
1.170
|
1.090
|
1.180
|
1.180
|
1.180
|
Announcement Date
|
12/03/20
|
11/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3.515
|
1.826
|
4.341
|
14.7
|
8.945
|
17.54
|
14.63
|
33.54
|
EBITDA
1 |
-35.75
|
-24.34
|
-48.34
|
-21.79
|
-24.04
|
-25.5
|
-23.18
|
-10.02
|
EBIT
1 |
-38.88
|
-26.45
|
-49.21
|
-22.52
|
-24.73
|
-21.93
|
-29.03
|
-21.42
|
Operating Margin
|
-1,106%
|
-1,448.36%
|
-1,133.63%
|
-153.17%
|
-276.5%
|
-125.06%
|
-198.38%
|
-63.87%
|
Earnings before Tax (EBT)
1 |
-19.23
|
-21.92
|
-43.27
|
-25.81
|
-23.28
|
-21.48
|
-25.77
|
-23.88
|
Net income
1 |
-11.71
|
-20.65
|
-43.02
|
-26.27
|
-21.49
|
-21.48
|
-25.77
|
-23.88
|
Net margin
|
-333.12%
|
-1,130.83%
|
-990.99%
|
-178.69%
|
-240.2%
|
-122.5%
|
-176.14%
|
-71.19%
|
EPS
2 |
-0.0800
|
-0.1400
|
-0.2600
|
-0.1500
|
-0.1200
|
-0.1133
|
-0.1260
|
-0.1175
|
Free Cash Flow
1 |
-
|
-
|
-
|
0.646
|
-29.24
|
-5.2
|
-24.95
|
-23.7
|
FCF margin
|
-
|
-
|
-
|
4.39%
|
-326.89%
|
-29.65%
|
-170.52%
|
-70.67%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/03/20
|
11/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.9
|
2.27
|
1.168
|
5.237
|
4.553
|
2.998
|
1.915
|
2.386
|
3.225
|
1.246
|
2.118
|
1.444
|
1.124
|
1.142
|
13.92
|
0.7445
|
EBITDA
1 |
-11.89
|
-6.644
|
-28.05
|
-6.214
|
-4.055
|
-5.058
|
-6.466
|
-6.471
|
-4.854
|
-6.529
|
-6.187
|
-6.486
|
-6.275
|
-6.435
|
-6.63
|
-7.65
|
EBIT
1 |
-
|
-6.843
|
-28.24
|
-6.396
|
-4.234
|
-5.251
|
-6.639
|
-6.642
|
-5.024
|
-6.705
|
-6.362
|
-6.661
|
-8.104
|
-8.626
|
3.827
|
-9.886
|
Operating Margin
|
-
|
-301.45%
|
-2,417.64%
|
-122.13%
|
-92.99%
|
-175.15%
|
-346.68%
|
-278.37%
|
-155.78%
|
-538.12%
|
-300.38%
|
-461.29%
|
-721.19%
|
-755.33%
|
27.5%
|
-1,327.94%
|
Earnings before Tax (EBT)
1 |
-14.96
|
-8.846
|
-28.01
|
-7.093
|
-6.782
|
-5.575
|
-6.362
|
-6.207
|
-5.203
|
-7.158
|
-4.714
|
-6.558
|
-7.987
|
-8.526
|
2.356
|
-9.886
|
Net income
1 |
-14.92
|
-7.823
|
-28.99
|
-7.087
|
-6.763
|
-6.069
|
-6.354
|
-4.372
|
-5.229
|
-7.11
|
-4.775
|
-6.542
|
-7.991
|
-8.518
|
2.045
|
-9.87
|
Net margin
|
-1,657.78%
|
-344.63%
|
-2,482.02%
|
-135.33%
|
-148.54%
|
-202.43%
|
-331.8%
|
-183.24%
|
-162.14%
|
-570.63%
|
-225.45%
|
-453.05%
|
-711.12%
|
-745.86%
|
14.69%
|
-1,325.65%
|
EPS
2 |
-0.1000
|
-0.0500
|
-0.1700
|
-0.0400
|
-0.0400
|
-0.0400
|
-0.0300
|
-0.0300
|
-0.0300
|
-0.0400
|
-0.0200
|
-0.0400
|
-0.0417
|
-0.0467
|
0.0100
|
-0.0500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/08/20
|
10/11/21
|
10/03/22
|
12/05/22
|
11/08/22
|
10/11/22
|
09/03/23
|
11/05/23
|
10/08/23
|
09/11/23
|
07/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
0.65
|
-29.2
|
-5.2
|
-25
|
-23.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.44
|
-
|
-
|
0.41
|
0.67
|
-
|
-
|
0.5
|
Capex / Sales
|
12.52%
|
-
|
-
|
2.81%
|
7.53%
|
-
|
-
|
1.49%
|
Announcement Date
|
12/03/20
|
11/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Last Close Price
1.18
USD Average target price
5.2
USD Spread / Average Target +340.68% Consensus |
1st Jan change
|
Capi.
|
---|
| +7.34% | 223M | | +17.96% | 47.02B | | +48.77% | 41.86B | | +1.17% | 41.76B | | -4.27% | 28.8B | | +11.42% | 26.05B | | -21.39% | 19.15B | | +4.86% | 12.55B | | +27.29% | 12.34B | | -3.50% | 11.82B |
Other Biotechnology & Medical Research
|